Regeneron Pharmaceuticals (NASDAQ:REGN) Director Bonnie Bassler Sells 1,500 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Bonnie Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $801.01 on Friday. The stock’s fifty day simple moving average is $735.23 and its 200-day simple moving average is $626.08. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $84.19 billion, a price-to-earnings ratio of 19.18, a P/E/G ratio of 2.42 and a beta of 0.39. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $816.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $12.46 EPS. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.4%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Royal Bank Of Canada raised their target price on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 29th. Wells Fargo & Company boosted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. Scotiabank increased their price target on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research note on Monday, November 24th. Citigroup upped their price target on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, HSBC assumed coverage on Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a “buy” rating and a $255.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $791.05.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America upgraded REGN from “Underperform” to “Buy” and raised its price target to $860, citing improving fundamentals and multiple 2026 catalysts — a major analyst reversal that boosts buy-side confidence. Regeneron upgraded by Bank of America
• Positive Sentiment: Shares hit a new 52-week high following recent analyst upgrades, signaling momentum and renewed institutional interest. Regeneron Hits New 52-Week High
• Positive Sentiment: Truist raised its price target to $820 and keeps a “Buy” rating, adding incremental upward pressure to consensus valuation. Truist raises price target
• Positive Sentiment: Broader analyst coverage has tilted more favorable (multiple firms raising ratings/targets and 21-analyst summaries highlighting improving outlook), supporting demand from momentum and fundamental buyers. 21 analysts assess REGN
• Positive Sentiment: Zacks highlights Regeneron’s history of beating estimates and argues the firm has the setup to beat again, which can lift expectations heading into future earnings. Zacks on earnings
• Neutral Sentiment: Unusual options activity was observed, indicating elevated trader interest/hedging around recent news — can amplify short-term volatility but is ambiguous on direction. Unusual options activity
• Neutral Sentiment: Comparative coverage (e.g., REGN vs ILMN) offers valuation context for investors but is not an immediate catalyst. REGN vs ILMN analysis
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at ~$800 (filed with the SEC), which can be viewed negatively by some investors even though the dollar amount is modest relative to market cap. Insider sale SEC filing

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Board of the Pension Protection Fund bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $31,000. Salomon & Ludwin LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $31,000. Caitlin John LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter valued at $34,000. Finally, Traub Capital Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $38,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.